Rivas Capital

Investor type Family Investment Office
Founders Carlos Gonzalez

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 22
Average round size
info
The average size of a deal this fund participated in
$43M
Portfolio companies 15
Rounds per year 2.00
Lead investments 2
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.32
Exits 2
Key employees 1

Areas of investment

  • Biotechnology
  • Medical
  • Health Care
  • Machine Learning
  • Artificial Intelligence
Summary

Rivas Capital is the famous VC, which was founded in 2011. The venture was found in North America in United States. The main office of represented VC is situated in the Cambridge.

The usual cause for the fund is to invest in rounds with 5-6 partakers. Despite the Rivas Capital, startups are often financed by Venture Capital Fund of New England, Matthew Sutton, IDP Industrial Development Partners. The meaningful sponsors for the fund in investment in the same round are Felicis Ventures, Matthew Sutton, Boston Seed Capital. In the next rounds fund is usually obtained by Oakhouse Partners, Visionnaire Ventures, Toyota Tsusho.

The fund has no exact preference in some founders of portfolio startups. In case when startup counts 4 or 5+ of the founder, the chance for it to get the investment is meager. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Besides, a startup needs to be aged 2-3 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Zipline, Greenlight Biosciences, Glympse Bio. Among the most successful fund investment fields, there are Energy, Chemical.

Considering the real fund results, this VC is 2 percentage points more often commits exit comparing to other organizations. The common things for fund are deals in the range of 10 - 50 millions dollars. The important activity for fund was in 2018. The fund is constantly included in less than 2 deals per year.

The fund was created by Carlos Gonzalez.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Rivas Capital:
Typical Co-investors
Rivas Capital is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Rivas Capital:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Acacia Partners Austin, Texas, United States
Bloom Equity County Dublin, Dublin, Ireland
Changan Assets China, Shanghai
ED&F Man Capital Markets New York, New York, United States
FedEx Memphis, Tennessee, United States
for Startups, Inc. Chiba Prefecture, Japan, Tateyama
Harmony Riverside Beijing, Beijing, China
Huamei International China, Guangdong, Guangzhou
Jiahe Yipin Beijing, China, Shunyi
JL Capital Central, Central Region, Singapore
Mahanusa Capital Indonesia, Jakarta, Jakarta Raya
Nadal Investments -
NextWorld Capital California, San Francisco, United States
Omega Advisors New York, New York, United States
Pathfinder Asset Management British Columbia, Canada, Vancouver
Plexus Capital Charlotte, North Carolina, United States
Techstars Kansas City Accelerator Kansas City, Missouri, United States
Zhuhai Titans Electronics Technology Power Group China, Guangdong, Zhuhai

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Clarify Health Solutions

Analytics
Health Care
Information Technology
Machine Learning
Medical
Software
$150M05 Apr 2022 San Francisco, California, United States

NextRNA Therapeutics

Biotechnology
Health Care
Therapeutics
$46M01 Mar 2022 Cambridge, Massachusetts, United States

Greenlight Biosciences

Agriculture
AgTech
Biotechnology
Chemical
Fuel
Sustainability
$125M03 Feb 2022 Massachusetts, United States

Comgy

Consumer
$29M09 Nov 2021 Berlin, Berlin, Germany

Inari

Agriculture
AgTech
Biotechnology
Developer Platform
Embedded Systems
Environmental Engineering
Information Technology
Network Hardware
Security
$208M12 May 2021 Cambridge, Massachusetts, United States

Clarify Health Solutions

Analytics
Health Care
Information Technology
Machine Learning
Medical
Software
$115M16 Mar 2021 San Francisco, California, United States

Regenacy Pharmaceuticals

Biotechnology
Medical
Therapeutics
$30M25 Mar 2020 Massachusetts, United States

Frequency Therapeutics

Biotechnology
Genetics
Medical
$62M23 Jul 2019 Woburn, Massachusetts, United States

Frequency Therapeutics

Biotechnology
Genetics
Medical
$42M07 Jan 2019 Woburn, Massachusetts, United States
News
Inari Raises $208M in Series D Funding

– Inari, a Cambridge, Mass.-based developer of a platform to enable yield increase, raised $208m in Series D funding.
– The round was co-led by Flagship Pioneering with participation from Alexandria Venture Investments, Investment Corporation of Dubai, Banque Pictet on behalf of their clients and Rivas Capital and new investors G Squared and Pavilion Capital.
– The company intends to use the funds to further accelerate advancements across its science platform and product development for corn and soybeans in both North and South America.
– Founded by Flagship Pioneering in 2016, Inari is based in Cambridge, Massachusetts, with additional sites in West Lafayette, Indiana, and Ghent, Belgium.

Clarify Health Raises $115M in Series C Funding

– Clarify Health is a San Francisco, CA-based enterprise analytics company delivering real-world insights to healthcare organizations.
– The company raised $115m in Series C funding.
– The round was led by new investor Insight Partners, alongside Spark Capital, Concord Health Partners, and HWVP, with participation from the company’s largest investor, KKR, as well as Rivas Capital and Sigmas Group.
– In conjunction with the funding, Hilary Gosher, Managing Director at Insight Partners, and Will Reed, General Partner at Spark Capital, will be joining the company’s Board of Directors.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Rivas Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: